Magazine Article | May 27, 2015

Moving Human Clinical Trial Design Into The 21st Century

Source: Life Science Leader

By Keren Sookne, Contributing Writer

The pharmaceutical industry is facing a productivity crisis, with current trial design flaws leading to extremely high attrition rates. Despite increased R&D spending and advances in molecular biology, data collection, and analytical technologies, the number of approved medicines remains relatively constant.

The failure rate of new drugs is alarming, particularly in Alzheimer’s disease, with a recent review of Alzheimer’s drug clinical trials from 2002-2012 reporting a success rate of 0.4 percent.